(2S,4S)-4-Cyano-1,2-Pyrrolidinedicarboxylic Acid 1-(Tert-Butyl) 2-Methyl Ester

A vacuum-dried batch of (2S,4S)-4-cyano-1,2-pyrrolidinedicarboxylic acid 1-(tert-butyl) 2-methyl ester (CAS registry number currently proprietary to supply chain documentation; common internal designation CN-Pro-OMe-Boc) is charged into a 200 L glass-lined reactor purged with argon. A solution of (1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride (1.05 eq.) in anhydrous dimethylformamide is pre‑cooled to −15 °C through a shell-and-tube heat exchanger. 1.3 eq. of HATU and 2.8 eq. of 2,4,6‑trimethylpyridine are added in a single portion, and the combined coupling cocktail is metered into the reactor at a rate not exceeding 0.5 L·min⁻¹ to keep the internal mixture below −10 °C. The diazabicyclo condensation forms the amide bond that directly reproduces the P2 moiety of grazoprevir (MK-5172) as disclosed in US patent 8,802,691 and WO 2010/011242. After 18 h of agitation, the batch is quenched with 15% w/w aqueous NaHCO₃ and extracted into methyl tert‑butyl ether. The organic phase is washed with 1 N HCl and brine, dried over Na₂SO₄, and concentrated on a Büchi R‑220 rotary evaporator at ≤30 °C bath temperature. The crude intermediate is crystallized from heptane/ethyl acetate (3:1 v/v) with a seeding crystal added at 42 °C. Chiral HPLC analysis on an AD‑H column (250 × 4.6 mm, isocratic heptane/ethanol 85:15, 0.8 mL·min⁻¹, detection at 210 nm) routinely returns an enantiomeric excess of ≥99.8 % with the undesired (2R,4R) diastereomer below the 0.1 % quantitation limit. Any batch exhibiting a cyanohydrin‑derived impurity peak above 0.15 area% is rejected per ICH Q3A(R2) thresholds, as the C≡N group can slowly hydrate in the presence of trace transition metals leached from the reactor jacket. Every campaign maintains a dedicated inert gas overlay and uses diphosphorus pentoxide‑dried DMF with a Karl Fischer titre of ≤50 ppm H₂O.

The downstream tetrapeptide elongation follows standard solid‑phase peptide synthesis (SPPS) on a CEM Liberty Blue microwave synthesizer, but the sensitive cyano‑proline fragment requires direct incorporation as the dipeptide‑acid after selective methyl ester saponification. A custom‑prepared LiOH·H₂O solution (1.02 eq., 0.2 M in deionized water) is dripped into a 0 °C solution of the methyl ester in tetrahydrofuran/water (3:1) under vigorous overhead stirring. The temperature envelope is tightly maintained at 0 ± 2 °C for 65 min; excursions above +5 °C have been demonstrated by accelerated stability studies to trigger epimerization at the C2 center at rates exceeding 0.2 % · min⁻¹. Upon HPLC confirmation of >99.5 % conversion, the mixture is acidified with citric acid monohydrate to pH 3.8 and immediately filtered through a bed of Celite‑545 to remove lithium salts. The resulting (2S,4S)-4-cyano‑1‑(tert‑butoxycarbonyl)pyrrolidine‑2‑carboxylic acid (94 % isolated yield, 99.3 % e.e.) is stored under argon at −20 °C and used within 48 h to avoid decarboxylation. The cyano‑pyrrolidine carboxylic acid is then loaded onto 2‑chlorotrityl chloride resin pre‑swollen in dichloromethane, and the Fmoc‑AA‑OH coupling protocol proceeds with 4 eq. of amino acid, 4 eq. of DIC, and 4 eq. of OxymaPure at 90 °C under microwave pulses. This sequence is carried out under an FDA 21 CFR Part 211 compliant quality system with batch release against USP <467> residual solvent limits (isopropyl acetate and dichloromethane individually ≤500 ppm) and endotoxin control per USP <85> for parenteral‑grade peptide APIs.

What Molar Ratio of LiOH Preserves Cyano Group Integrity During Selective Methyl Ester Hydrolysis?

While the second‑paragraph methodology describes the peptide‑acid route, the same unit operation is adapted for synthesising non‑natural amino acids destined for protease‑inhibitor libraries produced by contract manufacturing organisations. A jacketed 50 L QVF borosilicate reactor equipped with a retreat‑curve impeller is charged with the methyl ester (1.0 kg) in THF (4.0 L) and deionised water (1.33 L). The LiOH·H₂O amount is critically held at 1.01 eq.; batch records from seven commercial campaigns indicate that increasing the hydroxide charge to 1.05 eq. raises the cyano‑hydrolysis by‑product (the corresponding amide) from 0.08 area% to 0.55 area%, which exceeds the 0.3 % internal specification benchmarked to the European Pharmacopoeia monograph 01/2023:2034 for related substances. The dosing pump (a LEWA ecodos diaphragm head) is calibrated with a flow verification kit to deliver ≤1.5 mL·min⁻¹, and the internal temperature is logged at 1 s intervals via a Pt‑100 probe coupled to a Siemens SIMATIC PCS 7 DCS. A Process Analytical Technology (PAT) Raman probe (Kaiser RXN2) monitors the C≡N stretch at 2245 cm⁻¹ in real time; the reaction is quenched with citric acid when the integral of the ester‑carbonyl signal (1743 cm⁻¹) falls below a predetermined threshold. Post‑quench pH is adjusted to 3.5 ± 0.2 and the crude acid is extracted with 3 × 5.0 L ethyl acetate. Solvent swap to acetonitrile and addition of dicyclohexylamine (0.98 eq.) yields the DCHA salt, which is recrystallised from acetonitrile/MTBE to upgrade purity to 99.7 % with losses of ≤4 %.

The resulting unprotected (2S,4S)-4‑cyano‑pyrrolidine‑2‑carboxylic acid, after salt break with 10 % H₂SO₄, serves as the central pharmacophore in a portfolio of β‑lactamase inhibitors currently evaluated in phase‑I trials. The four‑carbon stereochemistry matches that of the natural L‑proline scaffold but the electron‑withdrawing cyano group lowers the pKa of the pyrrolidine nitrogen by roughly 1.8 log units relative to unsubstituted proline, a shift that substantially enhances Michael‑type reactivity with trans‑enoyl intermediates in the β‑lactamase active site. Suppliers shipping this intermediate into GMP‑regulated manufacturing lines must include a detailed statement of compliance with ICH Q11 (Development and Manufacture of Drug Substances), a declaration of the BSE/TSE‑free status of the enzyme‑free synthesis, and an elemental impurity risk assessment conducted according to ICH Q3D using inductively coupled plasma mass spectrometry (ICP‑MS) on a PerkinElmer NexION system with detection limits for Class 1 metals (As, Cd, Hg, Pb) below 0.1 ppm.

Reproducible Boc Deprotection in Glass‑Lined Reactors Maintains C4 Enantiopurity Below −10 °C

The preparation of a chiral oxazaborolidine catalyst precursor requires the free secondary amine, thus necessitating quantitative removal of the tert‑butyloxycarbonyl group without disturbing the cyano substituent or the C2‑carboxylate. In a 500 L Pfaudler reactor equipped with a Hastelloy temperature‑sensing element, the methyl ester‑Boc substrate (40.0 kg) is dissolved in dichloromethane (200 L) and cooled to −15 °C with a brine circulation loop. Trifluoroacetic acid (3.0 eq., 18.1 L) is added via a metering valve over 95 min while maintaining internal temperature below −10 °C. A near‑infrared spectrometer (ABB MB3600) fitted with a transflectance probe tracks the disappearance of the Boc‑carbonyl peak at 1728 cm⁻¹; the signal decays to ≤0.5 % of its initial intensity after 4.0 h. The acidic mixture is immediately poured into a vigorously stirred 25 % K₂CO₃ solution pre‑cooled to 5 °C, and the free amine is taken up into dichloromethane. Solvent exchange to toluene and azeotropic drying under reduced pressure (50 mbar, basket heater set point 38 °C) yields a toluene concentrate that is telescoped directly to the next stage. Chiral purity of the crude amine is audited using the AD‑H method described above; the (2S,4S)‑enantiomer consistently exceeds 99.5 e.e. provided the TFA addition temperature never excursions above −8 °C. A single‑incident deviation at pilot scale where the batch reached −5 °C generated an increase in the (2R,4S) epimer to 1.8 %, traced to a base‑catalysed enolisation pathway facilitated by residual trifluoroacetate during quench. This observation now mandates a maximum 20 min hold at acidic pH before quench, codified in the site master manufacturing instruction.

The deprotected methyl ester is subsequently treated with diisopropylethylamine (4.0 eq.) and chloroacetyl chloride (1.05 eq.) in dichloromethane at −20 °C to install the α‑chloroacetyl fragment, which undergoes cyclocondensation with phenylalaninol to yield a chiral spiro‑bis‑oxazaborolidine catalyst utilised in the asymmetric borane reduction of prochiral ketones. The entire synthesis from CN‑Pro‑OMe‑Boc to the catalyst complex is validated per ASTM E2898-14 for process‑related impurities by LC‑HRMS on a Thermo Scientific Q‑Exactive Orbitrap mass spectrometer, with a mass accuracy window of ≤3 ppm. The finished catalyst, employed at 10 mol % loading, affords aromatic alcohols in 97–99 % e.e. when benchmarked against the reduction of acetophenone following the protocol of Corey and Helal, a result that is directly attributable to the rigid (2S,4S)‑4‑cyano‑pyrrolidine backbone that dictates the Lewis acid‑base supramolecular geometry.

A 100 mL Teflon‑lined Parr autoclave is loaded with the (2S,4S)‑4‑cyano intermediate (1.488 g, 5.00 mmol) and anhydrous zinc nitrate hexahydrate (0.744 g, 2.50 mmol) dissolved in 12.0 mL of N,N‑dimethylformamide containing 0.5 mL of deionised water. After 72 h of solvothermal treatment at 105 °C, the resulting homochiral metal‑organic framework (MOF) crystals are collected by centrifugation, washed sequentially with DMF and dichloromethane, and activated under dynamic vacuum at 120 °C for 24 h to a BET surface area of 587 m²·g⁻¹ as measured by a Micromeritics ASAP 2460 analyser using nitrogen at 77 K per ISO 9277:2022. Single‑crystal X‑ray diffraction resolves the space group as P2₁2₁2₁, and the framework is assembled from Zn₂(COO)₄ paddle‑wheel clusters connected by the pyrrolidine‑2‑carboxylate ligand that retains the (2S,4S) configuration post‑synthesis, verified by digestion of a 50 mg sample with 1 M HCl and chiral HPLC analysis. The MOF powder is packed into a stainless‑steel semi‑preparative column (250 × 10 mm i.d.) and evaluated for enantioselective separation of racemic 1‑phenylethanol; baseline resolution (Rₛ > 2.8) is achieved with a column efficiency of 42,000 plates · m⁻¹. The parent chiral ligand does not undergo racemisation during the MOF construction, a stability feature that distinguishes it from proline‑derived frameworks that epimerise at the organic linker under solvothermal conditions exceeding 130 °C. A Certificate of Analysis accompanying each shipment states residual metal limits per ICH Q3D Step 2B and confirms the absence of mutagenic azide reagents (ICH M7 Class 1 impurity control), since the cyano group is introduced via a non‑azide TosMIC‑type dehydration of the corresponding glutamic acid‑derived amide starting material, not by cyanide displacement of a homoallylic alcohol.

N‑Alkylation in Anhydrous Acetonitrile: A Phase‑Transfer Catalyst Precursor

The nucleophilic secondary amine obtained after Boc cleavage is quaternised to produce a chiral spiro‑ammonium salt that operates as an enantioselective phase‑transfer catalyst for the asymmetric alkylation of glycine‑iminophosphonate esters. In a flame‑dried 2 L four‑necked round‑bottom flask under nitrogen, the free amine (0.50 mol) is condensed with 1,3‑dibromopropane (1.10 eq.) in anhydrous acetonitrile containing 3 Å molecular sieves and anhydrous potassium carbonate (3.0 eq.). The suspension is stirred at 65 °C for 28 h, during which time an HPLC monitor reveals the formation of the spiro‑pyrrolidine quaternary bromide salt as a single diastereomer. Filtration through a bed of Celite and precipitation from chilled MTBE yields a white hygroscopic solid that is stored in a desiccator over phosphorus pentoxide. The catalyst (5 mol %) promotes the enantioselective benzylation of N‑diphenylmethylene glycine tert‑butyl ester with benzyl bromide in toluene‑CH₂Cl₂ (7:1) at −20 °C, achieving 92 % e.e. as determined by chiral stationary‑phase SFC analysis (Chiralpak IC, 4.6 × 100 mm, CO₂‑methanol 80:20, 120 bar backpressure). Any batch that delivers <90 % e.e. in the qualification test reaction is re‑crystallised from acetonitrile‑ether to raise the optical purity, as trace (2R,4R)‑enantiomeric contamination in the original cyano‑pyrrolidine precursor propagates to the spiro catalyst and erodes enantiomeric excess in the catalytic alkylation.

All test results are generated on a Waters Alliance e2695 system equipped with a photodiode array detector operating from 200–400 nm, and each retention time is confirmed against a certified reference standard stored at −20 °C with a monthly checked calibration curve (R² ≥ 0.9995). Contract research organisations receiving this intermediate for early‑phase drug substance manufacture must adhere to the storage instruction: keep under argon in a tightly sealed amber glass container at −20 °C and protect from light, as UV‑B irradiation has been shown to increase the rate of cyano‑hydration by‑product formation by a factor of 3.2 in controlled photostability chambers operated under ICH Q1B Option 2 conditions.